Additionally, the reliability of CMap as a potential drug prediction tool for the disease has been confirmed, and in the next study, we will focus on the effects of these small molecule drugs as HYAL2 inhibitors in glioma. The gene discussed is HYAL2; the disease is central nervous system cancer.